News and blogs
175 results found.
Selinexor recommended in draft final guidance for myeloma
The drug, selinexor has been recommended by NICE in final draft guidance for use in people with myeloma if previous treatment has failed.
How a Yorkshire house led to five pioneering research projects
Last year you raised an incredible £1.95m for Blood Cancer UK in the Omaze Million Pound House Draw. Find out more about the incredible research projects this is helping to support.
Simon Thomas launches new blood cancer projects
Blood Cancer UK reveals that the money from their latest partnership with Omaze UK is their largest single donation to date. The money has now been invested into research via the Omaze x Blood Cancer UK Research Fund.
Scotland drug regulators rule blood cancer isn't cost effective
Yescarta, the blood cancer drug is not to be made available on the NHS in Scotland even though it is in England. Blood Cancer UK says it highlights the inequality in access to blood cancer drugs across the UK.
£4 million research project to establish those with high risk of blood cancer
On World Cancer Day, Blood Cancer UK & The Leukemia & Lymphoma Society announced a £4 million research project into establishing those at high risk of blood cancer.
Blood cancer drug Tepkinly authorised for use on NHS
The drug for diffuse large B-cell lymphoma, Tepkinly, has been authorised for use on the NHS as a third line treatment.
From despair to hope: The Matthew Wilson Multiple Myeloma Fund
Matthew Wilson establishes the Matthew Wilson Multiple Myeloma Fund (MWMMF) at Blood Cancer UK.
Research links childhood CT scan exposure to increased blood cancer risk
In new research, scientists have linked increased CT scan exposure to an increased risk of blood cancer in younger people.
How our research gave vaccine answers to people with blood cancer
Read about how our scientists were able to understand the effectiveness of the COVID-19 vaccine for clinically extremely vulnerable people.
The stolen legacy of Henrietta Lacks
Taken without her knowledge, Henrietta's 'immortal' cells have had an everlasting impact on research and medical ethics.
New non-Hodgkin lymphoma drug
A drug for non-Hodgkin lymphoma, epcoritamab, has been authorised for use in the UK for adults.
Zanabrutinib recommended for adults with CLL in the UK
Zanubrutinib has been recommended for adults with the blood cancer, chronic lymphocytic leukaemia (CLL) in England.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
People with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
What we can achieve with £1 million
We're proud to announce We’ve invested over £1 million funding five research projects, across five different blood cancers
The story of Dr Jane C Wright, pioneer of blood cancer research
To mark the start of Black History Month, we share the story of Dr Jane C Wright, a true pioneer in the field of blood cancer research
The father of the blood bank - Charles R. Drew
For Black History Month, we are celebrating Charles R. Drew who was an African American surgeon and researcher who pioneered in the field of blood transfusions, blood storage and created the first blood banks.
Myeloma drug approved for use
A new treatment for those with the blood cancer myeloma has been approved for use by NICE. It could benefit thousands.
Ruxolitinib approved for treatment of polycythaemia vera in England and Wales
The drug, ruxolitinib, has been recommended for use by NICE to treat the blood cancer polycythaemia vera in those whose disease is resistant or intolerant to the treatments hydroxycarbamide/hydroxyurea.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
The Scottish Medicines Consortium has approved two blood cancer treatments for use on the NHS in Scotland.
National Cancer Research Institute to close.
Blood Cancer UK's Sarah McDonald said it's sad that this long-standing, multi-partner collaboration is winding down.